Robert Bissonnette
0000-0001-5927-6587
8 papers found
Refreshing results…
Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non‒Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular Psoriasis
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
Persistence of inflammatory phenotype in residual psoriatic plaques in patients on effective biologic therapy
Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Missing publications? Search for publications with a matching author name.